Method for drug loading in liposomes

• US 20100247629A1
• Filed: 06/09/2010
• Published: 09/30/2010
• Est. Priority Date: 11/14/2003
• Status: Abandoned Application

• Current Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Hebrew University of Jerusalem)
• Original Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (Hebrew University of Jerusalem)
• Inventors: Barenholz, Yechezkel, Gabizon, Alberto A.
• Application Number:
  US12/802,545
• Publication Number:
  US 20100247629A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A liposome composition having a protonatable therapeutic agent entrapped in the form of a salt with a glucuronate anion is disclosed. Methods for preparing the composition using an ammonium ion transmembrane gradient having glucuronate as the counterion are also disclosed. In one embodiment where the protonatable agent is doxorubicin, the method of the invention has comparable loading efficiency, faster release rate, without compromising the therapeutic efficacy compared to loading with an ammonium ion gradient having sulfate as the counterion.

Claims

1. A method of preparing liposomes, comprising forming liposomes having an internal compartment and a bilayer lipid membrane, said liposomes having a concentration gradient of ammonium glucuronate across their bilayer lipid membranes;

and contacting the liposomes with an ionizable therapeutic agent to achieve transport of the agent into the internal compartment.

2. The method of claim 1, wherein said contacting comprises contacting the liposomes with an ionizable anthracycline therapeutic agent.

3. The method of claim 2, wherein said contacting comprises contacting the liposomes with an ionizable anthracycline therapeutic agent selected from doxorubicin, daunorubicin, and epirubicin.

4. The method of claim 1, wherein said forming liposomes includes (i) preparing a suspension of liposomes, each liposome in the suspension having at least one internal aqueous compartment that contains ammonium glucuronate at a first concentration, said liposomes suspended in an external bulk medium comprising ammonium glucuronate at the first concentration;

(ii) reducing the first concentration of ammonium glucuronate in the external bulk medium to a lower, second concentration of ammonium glucuronate, thereby establishing an ammonium ion concentration gradient across lipid bilayers of the liposomes.

5. The method of claim 4, wherein said reducing is achieved by dilution, dialysis, diafiltration, or ion exchange.

6. A method for loading a protonatable compound into pre-formed liposomes, comprising:

preparing a suspension of liposomes having a greater concentration of ammonium glucuronate inside the liposomes than outside the liposomes thereby establishing an ammonium ion concentration gradient from the inside to outside of the liposomes;

wherein said gradient is capable of active transport of said protonatable compound towards the inside of the liposomes, adding an amount of protonatable compound to the suspension, and allowing said protonatable compound to transport into said liposomes to achieve a content of said protonatable compound inside the liposomes to be greater than that outside of the liposomes.

7. The method of claim 6, wherein said preparing comprises forming the liposomes in the presence of an ammonium glucuronate solution having a first concentration;

entrapping said ammonium glucuronate solution of said first concentration inside said liposomes; and

reducing said first concentration of said ammonium glucuronate solution outside of the liposomes to a second concentration which is less than that of said first concentration.

8. The method of claim 7, wherein said protonatable compound is an anthracycline antibiotic.

9. The method of claim 8, wherein said anthracycline antibiotic is doxorubicin or daunorubicin.